STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLNO
  4. [Form 4] SOLENO THERAPEUTICS INC Insider Trading Activity

Soleno Therapeutics (SLNO) SVP granted RSUs and 11,900-share stock option

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Soleno Therapeutics officer Patricia C. Hirano reported new equity awards. On January 21, 2026, she received 10,400 shares of Common Stock in the form of restricted stock units (RSUs), with each RSU representing one future share. These RSUs are scheduled to vest 100% on December 15, 2027, if she continues as a service provider under the company’s equity plan through that date.

On the same day, she was also granted an employee stock option for 11,900 shares of Common Stock at an exercise price of $43.65 per share. One forty-eighth of these option shares start vesting on February 1, 2026 and then monthly thereafter, contingent on continued service, and the option expires on January 21, 2036. After these transactions, she beneficially owned 22,702 shares of Common Stock directly, along with the newly granted option.

Positive

  • None.

Negative

  • None.
Insider Hirano Patricia C
Role SEE REMARKS
Type Security Shares Price Value
Grant/Award Employee stock option (right to buy) 11,900 $0.00 --
Grant/Award Common Stock 10,400 $0.00 --
Holdings After Transaction: Employee stock option (right to buy) — 11,900 shares (Direct); Common Stock — 22,702 shares (Direct)
Footnotes (1)
  1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hirano Patricia C
(Last) (First) (Middle)
100 MARINE PARKWAY, SUITE 400
(Street)
REDWOOD CITY CA 94065
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SEE REMARKS
3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/21/2026 A 10,400(1) A $0 22,702(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee stock option (right to buy) $43.65 01/21/2026 A 11,900 (3) 01/21/2036 Common Stock 11,900 $0 11,900 D
Explanation of Responses:
1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.
2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
3. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.
Remarks:
Officer title: Senior Vice President, Regulatory Affairs
/s/ Anish Bhatnagar, Attorney-in-Fact 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did SLNO officer Patricia C. Hirano report on this Form 4?

Patricia C. Hirano reported two equity awards dated January 21, 2026: an acquisition of 10,400 shares of Common Stock in the form of restricted stock units (RSUs) and a grant of an employee stock option covering 11,900 shares of Common Stock.

How many Soleno Therapeutics (SLNO) shares does Patricia C. Hirano own after these transactions?

Following the reported transactions, Patricia C. Hirano beneficially owned 22,702 shares of Soleno Therapeutics Common Stock directly, in addition to holding an option to purchase 11,900 shares.

What are the vesting terms of the 10,400 RSUs granted to the SLNO officer?

The 10,400 RSUs granted to Patricia C. Hirano will vest 100% on December 15, 2027, provided she continues to be a service provider under Soleno Therapeutics’ 2014 Equity Incentive Plan through that date. Each vested RSU entitles her to receive one share of Common Stock.

What are the key terms of the 11,900-share stock option granted to Patricia C. Hirano at Soleno Therapeutics?

The employee stock option covers 11,900 shares of Common Stock at an exercise price of $43.65 per share. One forty-eighth of the shares subject to the option vest on February 1, 2026 and on each one-month anniversary thereafter, subject to her continued service. The option expires on January 21, 2036.

Is the Form 4 transaction for SLNO a purchase or a grant of equity awards?

The Form 4 reflects grants of equity awards to Patricia C. Hirano: RSUs and a stock option. The reported transaction codes are "A" for acquisition, and the transaction prices per share for the grants are shown as $0, consistent with awards granted under the company’s equity plan.

What is Patricia C. Hirano’s role at Soleno Therapeutics (SLNO)?

In this filing, Patricia C. Hirano is identified as an officer of Soleno Therapeutics, with the remarks specifying her title as Senior Vice President, Regulatory Affairs.